​Professor Francisco Leyva MD, FRCP, FACC

Professor of Cardiology, Consultant Cardiologist

Birmingham cardiologist, heart failure, resynchronization

 

Private secretary:       +44 7812 243176        johorton@sky.com                                                                                                                                                                       Appointments:            0121 5807151     ​   

​

COVID-19 ALERT

Please note that, following the UK Government's guidelines, outpatient and inpatient access to NHS and private facilities in UK have been restricted. Only patients who are considered critical can be assessed in the hospital environment. Patients may still be able to access private consultations via telephone or video links. If the condition is not considered critical by the Consultant, further assessments, diagnostic tests and procedures will have to wait until new goverment guidance emerges.

​

If you would like to consult with Professor F Leyva, please contact his secretary so that we can arrange a new or follow-up telehone or video link appointment. Plans for further tests and procedures will be planned after this consultation.                 

  • Prof. Leyva

  • The heart

  • Symptoms

  • Cardiac risk

  • Conditions

  • Investigations

  • Operations

  • Clinics

  • Research

  • International

  • Contact

  • More

     

    

    1. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management: A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in collaboration with the Heart Failure Society of America (HFSA), the American Society of Echocardiography (ASE), the American Heart Association (AHA), the European Association of Echocardiography (EAE) of the ESC and the Heart Failure Association of the ESC (HFA). • Endorsed by the governing bodies of AHA, ASE, EAE, HFSA, HFA, EHRA, and HRS. Task Force Chairs, Jean-Claude Daubert, Leslie Saxon, Philip B. Adamson, Angelo Auricchio, Ronald D. Berger, John F. Beshai, Ole Breithard, Michele Brignole, John Cleland, David B. DeLurgio, Kenneth Dickstein, Derek V. Exner, Michael Gold, Richard A. Grimm, David L. Hayes, Carsten Israel, Christophe Leclercq, Cecilia Linde, JoAnn Lindenfeld, Bela Merkely, Lluis Mont, Francis Murgatroyd, Frits Prinzen, Samir F. Saba, Jerold S. Shinbane, Jagmeet Singh, Anthony S. Tang, Panos E. Vardas, Bruce L. Wilkoff, Jose Luis Zamorano, Peer Reviewers, Inder Anand, Carina Blomström-Lundqvist, John P. Boehmer, Hugh Calkins, Serge Cazeau, Victoria Delgado, N.A. Mark Estes, David Haines, Fred Kusumoto, Paco Leyva, Frank Ruschitzka, Lynne Warner Stevenson, and Christian Tobias Torp-Pedersen. Europace 2012;14:1236-1286. 

    ​

    2. Leyva F, Taylor R, Foley PWX, Umar F, Mulligan LJ, Patel K, Stegemann B, Haddad T, Smith REA, Prasad S. Left Ventricular Midwall Fibrosis as a Predictor of Mortality and Morbidity after Cardiac Resynchronization Therapy in Patients with Non-Ischemic Cardiomyopathy. J Am Coll Cardiol 2012 (In press)​

    

    3. Nijjer S, Pabari P, Stegemann B, Palmieri V, Leyva F, Linde C, Freemantle N, Hughes A, Francis D. Limits of plausibility for predictors of response to cardiac resynchronisation therapy: systematic review and design steps for reliable research . J Am Coll Cardiol: Cardiovascular Imaging 2012 (In press)​


    4. Sack S, Wende C, Nägele H, Katz A, Bauer W, Barr C, Malinowski K, Schwacke H, Leyva F, Proff J, Berdyshev S, Paul V. Potential value of automated daily screening of cardiac resynchronization therapy defibrillator diagnostics for prediction of major cardiovascular events: results from Home-CARE (Home Monitoring in Cardiac Resynchronization Therapy) study. Eur J Heart Fail 2011;13:1019-1027.
    5. Mant J, Abdallah A-M, Swain S, Laramée P, for the Guideline Development Group (including F Leyva). Management of Chronic Heart Failure in Adults: Synopsis of the National Institute for Health and Clinical Excellence Guideline. Ann Intern Med  2011;155(4):252-259.

    ​

    6. Abdallah Al-Mohammad; Jonathan Mant; Philippe Laramee; Sharon Swain, for the Guideline Development Group (including F Leyva). Diagnosis and management of adults with chronic heart failure: summary of updated NICE guidance. BMJ 2010; 241.


    7. Leyva F, Fernandez-Lozano I, Morgan J. Cardioverter defibrillators: a cost or an investment? Europace 2010; 12:64    ​

     

    8. Leyva F, Foley P, Chalil S, Ratib K, Smith R, Prinzen F, Auricchio A. Cardiac resynchronisation therapy guided by late gadolinium-enhancement cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2011; 13:29-35​

    

    9. Boriani G, Burri H, Mantovani L, Maniadakis N, Leyva F, Kautzner J, Lubinski A, Braunschweig F, Jung W, Fernandez-Lozano I, Fattoree G. Device therapy and hospital reimbursement practices across European countries: a heterogeneous scenario. Europace 2011;13:59-65

    ​

    10. Wenzelburger F, Y Tan YT, Sanderson JE, Leyva F. Mitral annular peak systolic excursion on exercise: a simple diagnostic tool for heart failure and normal ejection fraction. Eur J Heart Fail 2011;13:953-960.​

    

    11. Foley P, Patel K, Irwin N, Sanderson JE, Frenneaux MP, Smith REA, Stegemann B, Leyva F. Cardiac resynchronization therapy in patients with heart failure and normal QRS duration: the RESPOND Study. Heart 201;97:1041-7

    ​

    12. Foley PWX, Chalil S, Ratib K, Smith REA, Prinzen F, Auricchio A, Leyva F. Fluoroscopic left ventricular lead position and the long-term clinical outcome of cardiac resynchronization therapy. Pacing Clin Electrophysiol 2011;34:785-797.

    13. Tan Y, Wenzelburger F, Lee E, Nightingale P, Heatlie G, Leyva F, Sanderson J. Reduced left atrial function on exercise in patients with heart failure and normal ejection fraction. Heart 2010; 96(13):1017-1023

    ​

    14. Leyva F, Foley PWX, Chalil S, Irwin N, Smith, REA. Female gender is associated with a better outcome after cardiac resynchronization therapy. Pacing Clin Electrophysiol 2010;34:82-80.​


     

    15. Foley PWX, Chalil S, Khadjooi K, Irwin N, Smith REA, Leyva F. Left ventricular reverse remodelling, long-term clinical outcome, and mode of death after cardiac resynchronization therapy. Eur J Heart Fail 2010;13:43-51.

    ​

    16. Foley P, Hamaad A, El-Gendi H, Leyva F. Incidental cardiac findings on computed tomography imaging of the thorax. BMC Res Notes 2010; 3:326.​


    

    17. Auricchio A, Brugada J, Ellenbogen KA, Gold MR, Leyva F for the CLEPSYDRA investigators. Assessment of a novel device-based diagnostic algorithm to monitor patient status in moderate-to-severe heart failure: rationale and design of the CLEPSYDRA study. Eur J Heart Fail. 2010; 12:1363-1371.

    ​

    18. Al- Mohammad A, Davis M, Dawda P, Foley P, Fuat A, Gilmour J, Hardman S, Kirwin G, Laramee P, Leyva F, Mant J, McIntyre H, Mindham R, Newberry N, Price A, Richards A, Ritchie G, Swain S, Turner C, Cowie A, Collinson P. Diagnosis and management of adults with chronic heart failure: summary of updated NICE guidance. Br Med J 2010; 25:341-345.​

    

    19. Schwartz G, Olsson A, Ballantyne C, Barter P, Holme I, Kallend D, Leiter L, Leitersdorf E, McMurray J, Shah P, Tardif J, Chaitman B, Duttlinger-Maddux R, Mathieson J, dal-OUTCOMES Committees and Investigators. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009; 158:896-901.

    ​

    20. Rademakers L, van Kerckhoven R, van Deursen C, Strik M, van Hunnik A, Kuiper M, Lampert A, Klersy C, Leyva F, Auricchio A, Maessen J, Prinzen F. Myocardial infarction does not preclude electrical and hemodynamic improvement on CRT in dyssynchronous canine hearts. Circulation Arrhyth and Electrophysiol 2010;3:361-368.​

    

    21. Williams LK, Ellery S, Patel K, Leyva F, Bleasdale RA, Phan T-T, Stegemann B, Paul V, Steendijk P, Frenneaux M. Short-Term Hemodynamic Effects of Cardiac Resynchronization Therapy in Patients With Heart Failure, a Narrow QRS Duration, and No Dyssynchrony. Circulation 2009; 120:1687-1694.

    ​

    22. Leyva F, Foley PWX, Stegemann B, Ward JA, Ng LL, Frenneaux MP, Regoli F, Smith REA, Auricchio A. Development and validation of a clinical index to predict survival after cardiac resynchronisation therapy. Heart 2009; 95:1619-1625.​

    

    23. Foley PWX, Stegemann B, Ng K, Ramachandran S, Proudler A, Frenneaux MP, Ng LL, Leyva F. Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronization therapy. Eur Heart J 2009; 30:2749-2757.

    ​

    24. Phan T-T, Abozguia K, Shivu GN, Ahmed I, Patel K, Leyva F, Frenneaux MP. Myocardial contractile inefficiency and dyssynchrony in Heart Failure with Preserved Ejection Fraction and narrow QRS complex. J Am Soc Echocardiogr; 23:201-206.​

    

    25. Phan TT, Abozguia K, Shivu GN, Ahmed I, Leyva F, Patel K, Frenneaux M. Increased atrial contribution to left ventricular filling compensates for impaired early filling during exercise in heart failure with preserved ejection fraction. J Card Fail 2009; 15:890-897.

    ​

    26. Foley PW, Khadjooi K, Ward JA, Smith RE, Stegemann B, Frenneaux MP, Leyva F. Radial dyssynchrony assessed by cardiovascular magnetic resonance in relation to left ventricular function, myocardial scarring and QRS duration in patients with heart failure. J Cardiovasc Magn Reson 2009; 11:50.​

    

    27. Foley, PWX, Muhyaldeen SA, Chalil S, Smith REA, Sanderson JE, Leyva F. Long term effects of upgrading from right ventricular pacing to cardiac resynchronization therapy in patients with heart failure. Europace 2009;11:495-501.

    ​

    28. Yousef ZR, Foley PW, Khadjooi K, Chalil S, Sandman H, Mohammed NU, Leyva F. Left ventricular non-compaction: clinical features and cardiovascular magnetic resonance imaging. BMC Cardiovascular Disorders 2009; 9:37.​

    

    29. Foley PWX, Chalil S, Khadjooi K, Jordan PJ, Smith REA, Leyva F. Cardiac resynchronisation pacing in patients unselected for mechanical dyssynchrony. Int J Cardiol  2009;143:51-56.

    ​

    30. Tan YT, Sanderson JE, Leyva F.  The pathophysiology of heart failure with normal ejection fraction: exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist and longitudinal motion. J Am Coll Cardiol 2009;54:36-46.​

     

    31. Foley PWX, Stegemann B, Smith REA, Sanderson JE, Leyva F. Cardiac resynchronization therapy in patients with mildly impaired left ventricular function. Pacing Clin Electrophysiol 2009; S1:106-109.

    ​

    32. Foley PWX, Addison CE, Whinney SB, Patel K, Cunningham D, Frenneaux MP, Leyva F. Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death after myocardial infarction: implications of international guidelines. Pacing Clin Electrophysiol 2009; 32 (Suppl 1):S131-134.​


     

    33. Ang K-L, Chin D, Leyva F, Foley P, Kubal C, Chalil S, Srinivasan L, Bernhardt L, Stevens S, Shenje L, Galinanes M. Randomized, controlled trial of intramuscular or intracoronary injection of autologous bone marrow cells into scarred myocardium during CABG versus CABG alone. Nature Clin Pract Cardiovasc Med 2008;5:663-670.

    ​

    34. Foley PWX, Stegemann B, Smith REA, Sanderson JE, Leyva F. Cardiac resynchronization therapy in patients with mildly impaired left ventricular function. Pacing Clin Electrophysiol 2009; S1:106-109.​

    ​

    35. Foley PWX, Addison CE, Whinney SB, Patel K, Cunningham D, Frenneaux MP, Leyva F. Implantable cardioverter defibrillator therapy for primary prevention of sudden cardiac death after myocardial infarction: implications of international guidelines. Pacing Clin Electrophysiol 2009; 32 (Suppl 1):S131-134.

    ​

    36. Foley P, Chalil S, Khadjooi K, Smith R, Frenneaux M, Leyva F. Long-term effects of cardiac resynchronization therapy in octogenarians: a comparative study with a younger population. Europace 2008;10:1302-1307.​

    ​

    37. Foley PWX, Chalil S, Ng K, Irwin N, Ramachandran S, Proudler A, El-Gendi H, Frenneaux MP, Ng L, Leyva F. Growth differentiation factor-15 predicts mortality and morbidity after cardiac resynchronisation therapy. Eur Heart J 2008; 29(Supp): 394.

    38. Khadjooi K, Foley PW, Chalil S, Anthony J, Smith REA, Frenneaux MP, Leyva F. Long-term effects of cardiac resynchronisation therapy in patients with atrial fibrillation. Heart 2008; 94:879-883.​

    ​

    39. Chalil S, Foley WX, Muhyaldeen SA, Patel K, Yousef ZR, Smith REA, Frenneaux MP, Leyva F. Late gadolinium enhancement cardiovascular magnetic resonance as a predictor of response to cardiac resynchronisation therapy in patients with ischaemic cardiomyopathy. Europace 2007;9:1031-1037.

    ​

    40. Chalil S, Stegemann B, Muhyaldeen SA, Khadjooi S, Foley PW, Smith R, Leyva F. Effect of posterolateral left ventricular scar on mortality and morbidity following cardiac resynchronization therapy. Pacing Clin Electrophysiol 2007; 30:1-9.​

    ​

    41. Chalil S, Stegemann B, Muhyaldeen S, Khadjooi K, Smith REA, Jordan PJ, Leyva F. Intraventricular dyssynchrony predicts mortality and morbidity after cardiac resynchronization therapy. J Am Coll Cardiol 2007;50:243-252.

    ​

    42. Chalil S, Yousef ZR, Muyhaldeen SA, Smith REA, Jordan P, Gibbs CR, Leyva F. Pacing-induced increase in QT dispersion predicts sudden cardiac death following cardiac resynchronization therapy. J Am Coll Cardiol 2006;47:2486-2492.​

    ​

    43. Fruhwald FM, Fahrleitner-Pammer A, Berger RD, Leyva F, Freemantle N, Erdmannn E, Gras D, Kappenberger L, L. T, Daubert J-C, Cleland JGF. Early and sustained effects of cardiac resynchronisation therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 2006; 28:1592-1597.

    ​

    44. Caro J, Guo S, Ward A, Chalil S, Malik F, Leyva F. Modelling the economic and health consequences of cardiac resynchronization therapy in the UK. Curr Med Res Opin 2006;22:1171-1179.​

    ​

    45. Yousef Z, Paul V, Leyva F. Cardiac resynchronization via the femoral vein: a novel method in cases with contraindications to the pectoral approach. Europace 2005;8:144-146.

    ​

    46. Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO, Leyva F, Proudler AJ, Coats AJS, Anker SD. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005;46:1019-26.​

    ​

    47. Godsland IF, Bruce R, Jeffs JA, Leyva F, Walton C, Stevenson JC. Inflammation markers and erythrocyte sedimentation rate but not metabolic syndrome factor score predict coronary heart disease in high socioeconomic class males: the HDDRISC study. Int J Cardiol 2004;97:543-50.

    ​

    48. Anker S, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos C, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel K, Leyva F, Hetzer R, Ponikowski P, Coats AJ. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107(15):1991-1997.​


    49. Doehner W, Schoene N, Rauchhaus M, Leyva-Leon F, Pavitt DV, Reaveley DA, Schuler G, Coats AJS, Anker SD, Hambrecht R. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002;105:2619-2624.    ​


    50. Leyva F, Rauchhaus M, Anker SD, Proudler AJ, Godsland IF, Stiefel P, Coats AJS, Poole-Wilson PA, Stevenson JC. Non-invasive assessment of vascular function: paradoxical vascular response to intravenous glucose in coronary heart disease. Eur Heart J 2000;21:39-44.    ​


    51. Leyva F, Anker SD, Chua T-P, Godsland IF, Poole-Wilson PA, Coats AJ. Loss of the normal coupling between the anaerobic threshold and insulin sensitivity in chronic heart failure. Heart 1999;82:348-351.    ​

     

     

    PEER-REVIEWED PAPERS​

    Continue

    Find us

    • facebook
    • googleplus
    • tbird

    Disclaimer: This website is for information only and should not be used for the diagnosis or treatment of medical conditions. All reasonable care has been taken in compiling the information but make no warranty as to its accuracy. You must consult a doctor for the diagnosis and treatment of medical conditions.